万维提示：
1、投稿方式：在线投稿。
2、官网网址：https://www.springer.com/journal/40519
3、投稿网址：https://www.editorialmanager.com/eawd/
4、官网邮箱：
Saranya.Sekar@springernature.com
（有关投稿问题，同行评审过程或稿件状态的查询）
Senthil.Bala@springer.com
（有关稿件出版或出版后更正中问题的查询）
sara.ho@biomedcentral.com
（有关期刊的任何其他查询或提交前的查询）
5、期刊刊期：双月刊，逢双月出版。
2021年4月25日星期日
投稿须知
【官网信息】
Submission guidelines
Instructions for Authors
Types of Papers
Review Articles
Overview papers on selected topics. Review articles are in general invited by the editors but suggestions by interested individuals may also be considered. Prospective authors should submit a formal and detailed proposal to the Editor, indicating the title and a brief outline of the content.
Manuscripts should provide an up-to-date and authoritative review and synthesis of existing literature. Review Articles should not exceed 7.500 words including an abstract of no more than 250 words, references, tables and figures. Keywords are requested.
Authors of reports on systematic reviews and meta-analyses are required to complete the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The PRISMA Statement consists of a 27-item checklist and a four-phase flow diagram that have been developed to help authors to improve the reporting of systematic reviews and meta-analyses. The journal requires that the completed checklist and diagram are submitted with systematic reviews and meta-analyses; PRISMA information may be posted with accepted manuscripts as online-only supplementary materials at the request of the editors or the authors.
Original Articles
Accounts of research or clinical practice that should be based on original rather than confirmatory data. Typically, Original Articles will present new data derived from a sizable series of subjects or patients. Original Articles should not exceed 5.000 words including an abstract of no more than 250 words, references, tables and figures. Keywords are requested.
The journal supports initiatives to improve the performance and reporting of trials, part of which includes prospective registering and numbering of clinical trials. The International Committee of Medical Journal Editors (ICMJE) has implemented the World Health Organisation (WHO) definition of clinical trials which states that a clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. This definition includes phase I to Phase IV trials.
All clinical trials submitted to the journal must be registered with an approved ICMJE clinical trial registry (such as clinicaltrials.gov); EAWD accepts registration of clinical trials in any of the primary registries that participate in the World Health Organization International Clinical Trial Registry Platform. Authors must include the unique clinical trial number and the name of the registry on the manuscript’s title page.
Authors of reports on randomized controlled trials (RCTs) are required to complete the checklist outlined in the Consolidated Standards of Reporting Trials (CONSORT) Statement. The instructions and checklist are designed to ensure that information pertinent to the trial is included in the study report. EAWD requires that the CONSORT checklist is submitted with RCT manuscripts; CONSORT information may be posted with accepted manuscripts as online-only supplementary materials at the request of the editors or the authors.
Brief Reports
Short papers including data from preliminary studies, new approaches to clinical practice, replication studies that are primarily based on negative or confirmatory data. Brief Reports should have an abstract and should not exceed 2.500 words. 1-2 tables and figures and up to 10 references are permitted.
Case Reports
Short papers that illustrate either a previously unrecognized disorder or a new aspect of a known condition. Ethical and legal considerations require the protection of a patient’s anonymity. Case Reports should have an abstract and should not exceed 2.000 words. 1-2 tables and figures and up to 10 references are permitted.
Correspondence
Brief letters (maximum of 500 words including references; no tables or figures, no abstract, no keywords) providing pertinent comments on published articles will be considered and the authors concerned will be given a right to reply. Letters raising problems of general interest will also be considered.
Letter to the Editor
Letters to the editors are published in the Correspondence section. They must not exceed 1000 words, 3 references and 3 authors. They should not have an abstract. They should be addressed to the Editor-in-Chief. Submitted letters will be subject to shortening and editorial revision.
Editorial
The journal publishes also Editorials. Authors who wish to submit an editorial should first consult the journal’s Editor-in-Chief.
Clinical Symposia from invited contributors are published occasionally.
All Review articles, Original Articles, Brief Reports and Case Reports MUST include the following headings in the manuscript:
Level of evidence – at the end of the Abstract
Strength and limits - at the end of the Discussion
What is already known on this subject? - after the Discussion
What this study adds? – after “What is already known on this subject?”
All manuscripts MUST also include the “Declarations” section (please see below).
EVIDENCE–BASED MEDICINE
This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable at the bottom of the Abstract. Author assignments may be subject to review and modification by the Editor-in-Chief.
For example (author should include entire phrase) at the bottom of the Abstract:
“Level of Evidence: Level II, controlled trial without randomization”
EBM ratings will be based on a scale of 1-5 as follows:
• Level I: Evidence obtained from: at least one properly designed randomized controlled trials; systematic reviews and meta-analyses; experimental studies
• Level II: Evidence obtained from well-designed controlled trials without randomization.
• Level III: Evidence obtained from well-designed cohort or case-control analytic studies
• Level IV: Evidence obtained from multiple time series with or without the intervention, such as case studies. Dramatic results in uncontrolled trials might also be regarded as this type of evidence.
• Level V: Opinions of respected authorities, based on descriptive studies, narrative reviews, clinical experience, or reports of expert committees.
No level of evidence for: basic science, animal studies, cadaver studies.
Strength and limits
In a short paragraph explain the key strength and limits of the study. Be clear and specific. Please incorporate this in the manuscript at the end of the Discussion section under the heading “Strength and limits”.
What is already known on this subject?
In two or three sentences explain what the state of scientific knowledge was in this area before you did your study and why this study needed to be done. Be clear and specific. Please incorporate this in the manuscript after the Discussion section under the heading “What is already known on this subject?”.
What this study adds?
Give a simple answer to the question “What do we now know as a result of this study that we did not know before?”. Be brief, succinct, specific, and accurate. You might use the last sentence to summarise any implications for practice, research, policy, or public health. . Please incorporate this in the manuscript after “What is already known on this subject?” under the heading “What your study adds?”.
Manuscript Submission
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.
Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
Online Submission
Please follow the hyperlink “Submit manuscript” on the right and upload all of your manuscript files following the instructions given on the screen.
Please ensure you provide all relevant editable source files. Failing to submit these source files might cause unnecessary delays in the review and production process.
Editorial procedure
Single-blind peer review
This journal follows a single-blind reviewing procedure.
English Language Support
For editors and reviewers to accurately assess the work presented in your manuscript you need to ensure the English language is of sufficient quality to be understood. If you need help with writing in English you should consider:
Asking a colleague who is a native English speaker to review your manuscript for clarity.
Visiting the English language tutorial which covers the common mistakes when writing in English.
Using a professional language editing service where editors will improve the English to ensure that your meaning is clear and identify problems that require your review. Two such services are provided by our affiliates Nature Research Editing Service and American Journal Experts. Springer authors are entitled to a 10% discount on their first submission to either of these services, simply follow the links below
English language tutorial
Nature Research Editing Service
American Journal Experts
Please note that the use of a language editing service is not a requirement for publication in this journal and does not imply or guarantee that the article will be selected for peer review or accepted.
If your manuscript is accepted it will be checked by our copyeditors for spelling and formal style before publication.
Title Page
Please make sure your title page contains the following information.
Title
The title should be concise and informative.
Author information
The name(s) of the author(s)
The affiliation(s) of the author(s), i.e. institution, (department), city, (state), country
A clear indication and an active e-mail address of the corresponding author
If available, the 16-digit ORCID of the author(s)
If address information is provided with the affiliation(s) it will also be published.
For authors that are (temporarily) unaffiliated we will only capture their city and country of residence, not their e-mail address unless specifically requested.
Abstract
Please provide a structured abstract of 150 to 250 words which should be divided into the following sections:
Purpose (stating the main purposes and research question)
Methods
Results
Conclusion
For life science journals only (when applicable)
Trial registration number and date of registration
Trial registration number, date of registration followed by “retrospectively registered”
Keywords
Please provide 4 to 6 keywords which can be used for indexing purposes.
Declarations
All manuscripts must contain the following sections under the heading 'Declarations'.
If any of the sections are not relevant to your manuscript, please include the heading and write 'Not applicable' for that section.
To be used for all articles, including articles with biological applications
Funding (information that explains whether and by whom the research was supported)
Conflicts of interest/Competing interests (include appropriate disclosures)
Availability of data and material (data transparency)
Code availability (software application or custom code)
Authors' contributions (optional: please review the submission guidelines from the journal whether statements are mandatory)
Additional declarations for articles in life science journals that report the results of studies involving humans and/or animals
Ethics approval (include appropriate approvals or waivers)
Consent to participate (include appropriate statements)
Consent for publication (include appropriate statements)
Please see the relevant sections in the submission guidelines for further information as well as various examples of wording. Please revise/customize the sample statements according to your own needs.
Text
Text Formatting
Manuscripts should be submitted in Word.
Use a normal, plain font (e.g., 10-point Times Roman) for text.
Use italics for emphasis.
Use the automatic page numbering function to number the pages.
Do not use field functions.
Use tab stops or other commands for indents, not the space bar.
Use the table function, not spreadsheets, to make tables.
Use the equation editor or MathType for equations.
Save your file in docx format (Word 2007 or higher) or doc format (older Word versions).
Manuscripts with mathematical content can also be submitted in LaTeX.
LaTeX macro package (Download zip, 188 kB)
Headings
Please use no more than three levels of displayed headings.
Abbreviations
Abbreviations should be defined at first mention and used consistently thereafter.
Footnotes
Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.
Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols.
Always use footnotes instead of endnotes.
Acknowledgments
Acknowledgments of people, grants, funds, etc. should be placed in a separate section on the title page. The names of funding organizations should be written in full.
References
Citation
Reference citations in the text should be identified by numbers in square brackets. Some examples:
1. Negotiation research spans many disciplines [3].
2. This result was later contradicted by Becker and Seligman [5].
3. This effect has been widely studied [1-3, 7].
Reference list
The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text.
The entries in the list should be numbered consecutively.
If available, please always include DOIs as full DOI links in your reference list (e.g. “https://doi.org/abc”).
Journal article
Gamelin FX, Baquet G, Berthoin S, Thevenet D, Nourry C, Nottin S, Bosquet L (2009) Effect of high intensity intermittent training on heart rate variability in prepubescent children. Eur J Appl Physiol 105:731-738. https://doi.org/10.1007/s00421-008-0955-8
Ideally, the names of all authors should be provided, but the usage of “et al” in long author lists will also be accepted:
Smith J, Jones M Jr, Houghton L et al (1999) Future of health insurance. N Engl J Med 965:325–329
Article by DOI
Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. J Mol Med. https://doi.org/10.1007/s001090000086
Book
South J, Blass B (2001) The future of modern genomics. Blackwell, London
Book chapter
Brown B, Aaron M (2001) The politics of nature. In: Smith J (ed) The rise of modern genomics, 3rd edn. Wiley, New York, pp 230-257
Online document
Cartwright J (2007) Big stars have weather too. IOP Publishing PhysicsWeb. http://physicsweb.org/articles/news/11/6/16/1. Accessed 26 June 2007
Dissertation
Trent JW (1975) Experimental acute renal failure. Dissertation, University of California
Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see
ISSN.org LTWA
If you are unsure, please use the full journal title.
Authors preparing their manuscript in LaTeX can use the bibtex file spbasic.bst which is included in Springer’s LaTeX macro package.
……
